Last reviewed · How we verify
HE 10
HE 10 is a therapeutic agent in development by Huons Co., Ltd., currently in phase 3 clinical trials.
At a glance
| Generic name | HE 10 |
|---|---|
| Sponsor | Huons Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Limited publicly available information exists regarding the specific mechanism of action for HE 10. As a phase 3 candidate from Huons Co., Ltd., it is undergoing advanced clinical evaluation, but detailed mechanistic data have not been widely disclosed in accessible pharmaceutical databases.
Approved indications
Common side effects
Key clinical trials
- USC-Exos in Corpus Spongiosum Reconstruction for Hypospadias (NA)
- TEAS for Ipsilateral Shoulder Pain After Video-Assisted Thoracoscopic Lung Surgery (NA)
- Pilot Study to Identify and Validate Digital Biomarkers in Osteoarthritis of the Knee (NA)
- Glyceryl Trinitrate Gel Phonophoresis on Planter Fasciiatis (NA)
- Transcranial Magnetic Stimulation on Somtosensory Cortex Enhances Motor Learning in People With Stroke (NA)
- TEAS Combined With Triple Antiemetic Drugs to Prevent PONV in High-Risk Patients (NA)
- PRISM Intervention Study (NA)
- A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HE 10 CI brief — competitive landscape report
- HE 10 updates RSS · CI watch RSS
- Huons Co., Ltd. portfolio CI